Aap Implantate Ag · XETR:AAQ1
Aap Implantate — 7. DVFA Frühjahrskonferenz 2016
22 slides from Aap Implantate's conference presentation, May 9, 2016
Slide 1: aap Implantate AG Investor Presentation
aap Implantate AG Investor Presentation 7. DVFA Frühjahrskonferenz Frankfurt am Main Bruke Seyoum Alemu, CEO May 9, 2016
Slide 2: Safe Harbor Statement
Safe Harbor Statement Our publication may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual
Slide 3: aap Company Overview
aap Company Overview German based international MedTech company Listed in Frankfurt, Germany, Prime standard (XETRA: AAQ.DE) 2015*: Sales EUR 28 million, EBITDA EUR -1.9 million Operating with two Centres of Excellence Center of Excellence Trauma, Berlin Center of Excellence Biomaterials, Di
Slide 4: Implementation of Strategic Imperatives: Progress in FY/2015
Implementation of Strategic Imperatives Progress in FY/2015 Products Customers Accelerating Value-based Innovation Enhancing Market Access LOQTEQ®: Scheduled portfolio expansion; indication USA: In total conclusion of 12 distribution contracts; first coverage of more than 90% reached for treatme
Slide 5: Financial Figures FY/2015
Financial Figures FY/2015 (in EUR million) Sales FY/2015 FY/2014 Change Trauma 10.8 12.8 -16% Trauma - implants 10.3 12.2 -16% Trauma - biomaterials 0.5 0.6 -9% Other 1.5 1.8 -17% Sales continued operation 12.3 14.6 -16% Sales discontinued operation 15.7 16.0* -2% Group sales 28.0 30.6* -9% *Discont
Slide 6: Implementation of Strategic Imperatives
Implementation of Strategic Imperatives Getting focused on trauma – divesting aap Biomaterials Press Release dated March 22, 2016: aap Implantate AG signed a notarized share purchase agreement with a leading European private equity firm for the sale of 100% of the company shares in its subsidiary
Slide 7: 2016 Guidance
2016 Guidance Financial Figures Continued operation Sales: EUR 13.0 million – EUR 15.0 million with 20% growth in trauma products (FY/2015: EUR 12.3 million) EBITDA: EUR -5.5 million – EUR -3.9 million (FY/2015: EUR -6.8 million) Group (continued and discontinued operation) EBITDA incl. de
Slide 8: aap – Sum of the Parts
aap – Sum of the Parts aap Trauma aap Silver Technology addresses unmet need of the industry (infection prevention) Strong LOQTEQ® sales growth, CAGR 2011-2015 > 100% Strong IP, platform technology with a wide range of Strong IP, comprehensive portfolio for mainstream applications trauma as
Slide 9: A Transformed Business
A Transformed Business Strategic divestitures to grow aap’s Silver Technology applied in Strategic Divestitures Orthopaedics, Cardiology, Dental 2008 2009 2010 2011 2012 2013 2014 2016 and surgical instruments Dental √ Analytics √ Inflection Medical Aesthetics √ point Recon √ Contract √ Manufacturin
Slide 10: Platform Technology – LOQTEQ®
Platform Technology – LOQTEQ® Fundamentals Concept Application Protected by several global patents Mainstream trauma, lower & upper extremities Competitive Environment Entirely benchmarked against the market leader Synthes Stryker Zimmer S&N Königsee aap 10
Slide 11: Platform Technology – LOQTEQ®
Platform Technology – LOQTEQ® Portfolio and performance Portfolio Growth Track Record Comprehensive and procedure focused Driven by BRICS, SMIT and Europe Value Genuine alternative to the gold standard with new and additional features Clinical and economical advantages: Proposition Optimum ins
Slide 12: Platform Technology – LOQTEQ®
Platform Technology – LOQTEQ® Comprehensive portfolio Foot System 12
Slide 13: Platform Technology – Silver Coating
Platform Technology – Silver Coating Value based innovation Unmet Need Innovative Solution Infection prevention for medical devices Surgical Site Infection (SSI) ✓ Prevention of bacterial colonization ✓ Platform technology with broad application Biofilm formed on an TiAl6V4 ✓ Very high efficacy (in
Slide 14: Platform Technology – Silver Coating
Platform Technology – Silver Coating Competitive advantage aap Market Leader 1 Market Leader 2 Antibacterial agent micro-Ag / nano-Ag AgNO3 micro-Ag / nano-Ag Coating principle Single step: 4-step in 2 solutions: Multi-step: Electrochemical (PEO) Electrochemical (acidic anodization) & vacuum deposit
Slide 15: Platform Technology – Silver Coating: Regulatory path
Platform Technology – Silver Coating Regulatory path Results delivered Regulatory Path Comprehensive animal trials accomplished Short term targeted CE- and FDA-clearance Biocompatibility Efficacy Cytotoxicity In-vitro Irritation Ex-vivo CE CE Approval FDAFDA Approval Pin implant infection Sensitizat
Slide 16: Platform Technology – Magnesium Implants
Platform Technology – Magnesium Implants Value based innovation Unmet Need Innovative Solution Biocompatible and biodegradable metal implants Disadvantages of currently used metallic implants ✓ Bioabsorbable implants Need of second surgery for implant removal ✓ Platform technology with broad appli
Slide 17: aap – Roadmap
aap – Roadmap Unique, innovative, addressing unmet needs 17
Slide 18: Our Differentiated Business Model
Our Differentiated Business Model Strong IP portfolio for all Unique pure player in platform technologies: trauma focussing on fast LOQTEQ Technology growing segments of Silver Technology Magnesium Technology orthopaedics Innovation Market Product Customer International sales Comprehensive pro
Slide 19: Management Agenda 2016 and beyond
Management Agenda 2016 and beyond Implementation of strategic imperatives Products Customers Accelerating Value-based Innovation Enhancing Enhancing Market Market Access Access LOQTEQ®: Completion of LOQTEQ® portfolio with a focus Established Established countries: countries: Focus Focus on on
Slide 20: The New aap – Pure Trauma Company
The New aap – Pure Trauma Company Why invest in aap? Comprehensive IP protected platform technologies LOQTEQ® Technology, Silver Coating Technology, Magnesium Implants Technology Comprehensive product portfolio CE, FDA and SFDA approved; indication coverage > 90% for large bone fractures A
Slide 21: Shareholder structure
Shareholder structure Market Cap amounts to approx. EUR 45 million** Capital Stock: 30,670,056 million 13.37% Ratio Capital Management B.V., Netherlands Jürgen W. Krebs, Switzerland 12.72% Noes Beheer B.V., Netherlands 46.52% Taaleritehdas ArvoRein Equity Fund, Finland Deepblue Holding AG, Switzer
Slide 22: Contact
Contact aap Implantate AG Lorenzweg 5 12099 Berlin Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de Website: www.aap.de IR-app: 22